Pharmaresearch Bio파마리서치바이오
217950 · KONEX · ₩217950 · 파마리서치바이오
₩29,250▲ ₩50 (0.17%)End-of-day · Oct 30, 2026 · End-of-day prices.
Filings
- Insider shareholding report임원ㆍ주요주주특정증권등소유상황보고서Oct 29, 2026Open on DART
Predicted impact: Low
- 5%+ holding report주식등의대량보유상황보고서(일반)Oct 29, 2026Open on DART
Predicted impact: Low
- Exercise of Conversion Rights (4th Round)전환청구권행사 (제4회차)Oct 22, 2026Open on DART
Predicted impact: Medium
Convertible bond conversion adds shares; amount not given, small company so dilution could matter.
- Investor relations (IR) event기업설명회(IR)개최결과Oct 6, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최Sep 17, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최결과Jun 9, 2026Open on DART
- Investor relations (IR) event기업설명회(IR)개최May 21, 2026Open on DART
- Annual general meeting results정기주주총회결과Mar 27, 2026Open on DART
- Report on Appointment, Dismissal, or Mid-Term Resignation of Independent Directors독립이사의선임ㆍ해임또는중도퇴임에관한신고Mar 27, 2026Open on DART
- Annual report (Dec 2025)사업보고서 (2025.12)Mar 19, 2026Open on DART
- Audit report submitted감사보고서제출Mar 16, 2026Open on DART
- Notice of Reason for Concentrated Shareholders' Meeting Date주주총회집중일개최사유신고Mar 12, 2026Open on DART
- Reference Document for Proxy Solicitation of Voting Rights의결권대리행사권유참고서류Mar 12, 2026Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 12, 2026Open on DART
- Shareholders' meeting called주주총회소집결의Mar 6, 2026Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Mar 4, 2026Open on DART
- Acquisition of Convertible Bonds (Including Overseas Convertible Bonds) Before Maturity (5th Round)전환사채(해외전환사채포함)발행후만기전사채취득 (제5회차)Feb 24, 2026Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2025Open on DART
- Shareholder Register Closure for Cash/Stock Dividend (Record Date) Decision현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정Dec 16, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최결과Nov 6, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Oct 23, 2025Open on DART
- Conversion Right Exercise (3rd Series)전환청구권행사 (제3회차)Jun 20, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최결과Apr 30, 2025Open on DART
- Investor relations (IR) event기업설명회(IR)개최Apr 23, 2025Open on DART
- Annual general meeting results정기주주총회결과Mar 25, 2025Open on DART
- Audit report submitted감사보고서제출Mar 17, 2025Open on DART
- Annual report (Dec 2024)사업보고서 (2024.12)Mar 17, 2025Open on DART
- Shareholders' meeting called주주총회소집결의Mar 7, 2025Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 7, 2025Open on DART
- [Corrected] New Facility Investment, etc.[기재정정]신규시설투자등Dec 30, 2024Open on DART
- Determination of Shareholder Register Closure Period or Record Date주주명부폐쇄기간또는기준일설정Dec 16, 2024Open on DART
- Shareholder Register Closure for Cash/Stock Dividend (Record Date) Decision현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정Dec 16, 2024Open on DART
- Acquisition of Bonds Before Maturity After Issuance of Convertible Bonds (including Overseas Convertible Bonds) (3rd Series)전환사채(해외전환사채포함)발행후만기전사채취득 (제4회차)Nov 26, 2024Open on DART
- Investor relations (IR) event기업설명회(IR)개최결과Oct 29, 2024Open on DART
- Not designated as a company subject to unfaithful disclosure penalties불성실공시법인미지정Oct 22, 2024Open on DART
- Investor relations (IR) event기업설명회(IR)개최Oct 14, 2024Open on DART
- Notice of Designation as Unfaithful Disclosure Company (Reversal of Disclosure)불성실공시법인지정예고 (공시번복)Sep 30, 2024Open on DART
- Other Major Management Matters (Voluntary Disclosure)기타주요경영사항(자율공시)Aug 30, 2024Open on DART
- Investor relations (IR) event기업설명회(IR)개최결과May 17, 2024Open on DART
- Annual general meeting results정기주주총회결과Mar 25, 2024Open on DART
- Audit report submitted감사보고서제출Mar 15, 2024Open on DART
- Annual report (Dec 2023)사업보고서 (2023.12)Mar 15, 2024Open on DART
- Shareholders' meeting called주주총회소집결의Mar 7, 2024Open on DART
- Notice of shareholders' meeting주주총회소집공고Mar 7, 2024Open on DART
- 5%+ holding report주식등의대량보유상황보고서(약식)Feb 29, 2024Open on DART
- Results of Securities Issuance (Voluntary Disclosure) (5th Series CB)증권발행결과(자율공시) (제5회차 CB)Feb 22, 2024Open on DART
- Convertible bond issue decision주요사항보고서(전환사채권발행결정)Feb 19, 2024Open on DART
- Other Material Management Matters (Voluntary Disclosure) (Product Licence Approval for Rientok 100 Units (Clostridium Botulinum Toxin Type A))기타주요경영사항(자율공시)(리엔톡주100단위(클로스트리디움보툴리눔독소A형) 품목허가 승인)Feb 1, 2024Open on DART
- Other Material Management Matters (Voluntary Disclosure) (Defendant's Appeal Against First-Instance Ruling in Lawsuit to Revoke Administrative Disposition Such as Cancellation of Product Approval)기타주요경영사항(자율공시)(품목허가취소 등 행정처분 취소소송 1심 판결에 대한 피고 항소의 건)Jan 4, 2024Open on DART
- Other Material Matters (Voluntary Disclosure): Plaintiff's Appeal Against First-Instance Ruling in Lawsuit Seeking Cancellation of Orders for Recall and Disposal of Pharmaceutical Products, Suspension of Manufacturing, and Cancellation of Product Licence Revocation기타주요경영사항(자율공시)(의약품 회수·폐기 및 잠정 제조중지 등 명령 취소 및 품목허가취소처분 등 취소 소송의 1심 판결에 대한 원고 항소의 건)Dec 22, 2023Open on DART
Titles in Korean until English translations are added.
Also known as: Pharmaresearch Bio / 파마리서치바이오 / 217950 / KRX:217950
Source: KRX statistical information